Caribou Biosciences

CRBU Micro Cap

Healthcare · Biotechnology

Updated: Apr 5, 2026, 17:43 UTC

$1.94

-2.51% today

52W: $0.66 – $3.54

52W Low: $0.66 Position: 44.5% 52W High: $3.54

🔗 Compare Brokers

Key Metrics

P/E Ratio

—

Price-to-Earnings

Forward P/E

—

Forward Price/Earnings

P/S Ratio

16.8x

Price-to-Sales

EV/EBITDA

—

Enterprise Value/EBITDA

Div. Yield

—

Annual dividend yield

Market Cap

$187.5M

Market Capitalization

Revenue Growth

89.7%

YoY Revenue Growth

Profit Margin

—

Net profit margin

ROE

-78.97%

Return on Equity

Beta

2.46

Market sensitivity

Short Interest

7.64%

% of float sold short

Avg. Volume

1,245,557

Average daily volume

Valuation Analysis

Signal

N/A

vs. S&P 500 avg P/E (24.7x)

Analyst Consensus

Strong Buy

8 analysts

Avg. Price Target

$11.12

+473.45% upside

Target Range

$4.00 – $32.00

About the Company

Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies. The company develops Vispacabtagene Regedleucel, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.

Sector: Healthcare Industry: Biotechnology Country: United States Employees: 97 Exchange: NMS